Results 81 to 90 of about 6,619 (182)

Identification of drug repurposing candidates for the treatment of polycystic kidney disease

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 16, Page 5082-5101, August 2026.
Background and Purpose Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of end‐stage renal disease with limited treatment options. Drug repurposing offers a promising strategy to find effective treatments. Experimental Approach We identified birinapant, bardoxolone methyl and salicylic acid as repurposing candidates for ADPKD and
Alina Meyer   +9 more
wiley   +1 more source

Tolvaptan Improves Refractory Ascites and Overall Survival in Cirrhosis: A Meta-Analysis

open access: yesCurrent Internal Medicine Research and Practice Surabaya Journal
Introduction: Refractory ascites is a frequent complication associated with liver cirrhosis. Tolvaptan, a V2-receptor antagonist, has shown effectiveness in improving refractory ascites.
Chetan Kalal   +3 more
doaj   +1 more source

Hyponatremia correction is associated with increased brain‐derived neurotrophic factor levels: A pilot secondary analysis of a randomized, double‐blind, placebo‐controlled, crossover trial

open access: yesJournal of Neuroendocrinology, Volume 38, Issue 8, August 2026.
Abstract Chronic hyponatremia is associated with cognitive deficits, yet the underlying mechanisms remain elusive. A cerebral growth factor which is crucial for cognition and memory is brain‐derived neurotrophic factor (BDNF), but its role in hyponatremia has never been investigated.
Eszter Kustos‐Tóth   +6 more
wiley   +1 more source

Tolvaptan and its potential in the treatment of hyponatremia

open access: yes, 2008
Megan B Dixon, Y Howard LienDepartment of Medicine, University of Arizona, Arizona Kidney Disease and Hypertension Center, Tucson, Arizona, USAAbstract: Tolvaptan is a selective arginine vasopressin (AVP) V2 receptor blocker used to induce free water ...
Y Howard Lien, Megan B Dixon
core  

SHORT COMMUNICATION Hepatocellular Disposition and Transporter Interactions with Tolvaptan and Metabolites in Sandwich-Cultured Human Hepatocytes Running Title: Tolvaptan Disposition and DDIs in SCHH

open access: yes, 2020
: Tolvaptan is a selective V 2 -receptor antagonist primarily metabolized by CYP3A. The present study investigated the hepatocellular disposition of tolvaptan and the generated tolvaptan metabolites, DM-4103 and DM-4107, as well as the potential for drug-
K L R, J R S, ( Y L
core  

More Than a Question of Correlation: Characterization of the Evidentiary Basis for Biomarker Surrogates Used in European Marketing Authorizations

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1522-1536, June 2026.
Traditionally, clinical outcomes measuring how a patient feels, functions, or survives are preferred endpoints in clinical trials; however, some may take a long time to manifest in slowly developing diseases. Biomarkers, if properly validated, can serve as surrogate endpoints, acting as substitutes for clinical outcomes.
Renske Johanna Grupstra   +4 more
wiley   +1 more source

Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report

open access: yesBMC Nephrology, 2019
Background Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary disease characterized by the presence of renal cysts. Over time the expanding cysts lead to progressive renal failure.
Angela Maria Pellegrino   +3 more
doaj   +1 more source

Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan [PDF]

open access: yes, 2020
Background and objectives: Nephrolithiasis is a common health problem in autosomal dominant polycystic kidney disease (ADPKD) and significantly contributes to patient morbidity.
Bargagli, Matteo   +23 more
core   +1 more source

Potential amelioration of liver function by low-dose tolvaptan in heart failure patients

open access: yesToxicology Reports
Aim: This study aimed to evaluate the relationships between the pharmacokinetics of tolvaptan and its metabolites (DM-4103 and DM-4107) and liver injury in heart failure patients, using relevant laboratory test values and markers of hepatocyte injury and
Yasuaki Mino   +8 more
doaj   +1 more source

Prognostic Value of an Early Response to Tolvaptan and Its Clinical Implications in Patients With Cirrhosis and Hepatic Edema: A Nationwide Multicenter Cohort Study

open access: yesHepatology Research, Volume 56, Issue 6, Page 925-932, June 2026.
In a nationwide multicenter cohort, an early response to tolvaptan (≥ 1.5‐kg weight loss within 7 days) was independently associated with improved long‐term survival in patients with cirrhosis and hepatic edema. Early initiation before renal impairment or hyponatremia may optimize treatment response and prognosis. ABSTRACT Aim Hepatic edema indicates a
Kaori Koyano   +22 more
wiley   +1 more source

Home - About - Disclaimer - Privacy